| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
